-
Press Release
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
-
Story
The future of medicine is here -
Press Release
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
-
Press Release
Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition
-
Story
Take a visual tour of medicines that target RNA -
Story
Need for new heart disease medicines drives wave of potential therapies -
Story
Minion challenges assumptions about the genome -
Story
Giraffes have high blood pressure. Why don’t they drop dead? -
Story
Cancer spies find drug-beating covert cells -
Story
Building brain organoids to shed light on disease -
Story
Intractable tumor cells crippled -
Story
Factory foreman keeps liver’s line workers on task